|Bid||95.150 x 800|
|Ask||97.350 x 2200|
|Day's Range||97.000 - 97.350|
|52 Week Range||76.410 - 97.380|
|PE Ratio (TTM)||41.91|
|Earnings Date||Nov 20, 2018|
|Forward Dividend & Yield||2.00 (2.06%)|
|1y Target Est||102.45|
The companies in Minneapolis with the most openings for six-figure-salary jobs are the University of Minnesota, Boston Scientific Corp., Fairview Health Services, UnitedHealth Group and Allina Health, according to Ladders.
September 18, 2018 - Medtronic plc (MDT) today announced that the U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) to initiate a single-arm study to evaluate the CoreValve Evolut(TM)TAVR system in patients with bicuspid aortic valves who are at low risk of surgical mortality. Medtronic separately received FDA approval for revised commercial labeling for the CoreValve Evolut TAVR system that removed a precaution for the treatment of bicuspid severe aortic stenosis patients deemed at intermediate or greater risk for surgical aortic valve replacement.
The Fannin Innovation Studio was founded in 2005 and invests in the early-stage medical technology and life sciences companies.
September 17, 2018 - Medtronic plc (MDT) today announced it has joined the Catalyst CEO Champions For Change. This transformational diversity and inclusion initiative was launched by Catalyst - a global thought leader and partner in accelerating the progress of women at work for over 50 years. Accelerate progress in the representation of women, including women of color, in executive/senior level positions over five years.
On September 14, Boston Scientific (BSX) was trading at a forward PE (price-to-earnings) ratio of 24.4x, compared to the industry’s average PE ratio of 22.4x. Boston Scientific’s forward EV-to-EBITDA multiple is 19.1x, which is higher than the industry average of 16.7x. On September 14, Boston Scientific’s peers Abbott Laboratories (ABT), Edwards Lifesciences (EW), and Medtronic (MDT) had forward PE multiples of 21.7x, 28.4x, and 18.3x, respectively.
BSX stock is trading ~53.0% higher than its 52-week low of $24.54 reported on December 6, 2017. Over the last week, BSX stock has risen ~4.5%. BSX stock has risen ~11.6% over the last month. Year-to-date, BSX stock has reported stellar gains of ~52.0%.
Easily the biggest trend in investing has to be healthcare stocks. From rising and aging populations in the developed world to new middle-class consumers gaining access to healthcare for the first time in emerging markets, healthcare demand is only getting bigger by the day. All in all, the combination of the two factors makes the medical device stocks some of best plays in all of healthcare.
September 13, 2018 - Medtronic plc (MDT) was recognized today as one of the world`s leading companies for sustainability with its ranking on the Dow Jones Sustainability North America Index (DJSI North America) for the eleventh consecutive year. DJSI North America analyzes companies on a variety of sustainability criteria, including economic performance, environmental stewardship, social responsibility, and corporate governance. This adds to the recognition Medtronic received earlier this year through its continued inclusion in the FTSE4Good Index Series.
Thermo Fisher Scientific (TMO) announced on September 7, 2018, that the company will acquire Becton Dickinson’s (BDX) advanced bioprocessing business.
Thermo Fisher Scientific (TMO) announced on September 7, 2018, that the company offers end-to-end analytical solutions that comply with cannabis testing standards as defined by Health Canada.
Thermo Fisher Scientific (TMO) surpassed Wall Street analysts’ estimates for earnings per share (or EPS) and revenues during Q2 2018 and reported non-GAAP EPS of $2.75 on revenues of ~$6.1 billion during the quarter. The above chart compares the revenues since the first quarter of 2017.
Thermo Fisher Scientific (TMO) provides equipment, software, analytical instruments, reagents, consumables, and services. Thermo Fisher reported non-GAAP EPS of $2.75 on revenues of ~$6.1 billion, a 21.8% increase as compared to ~$5.0 billion during the second quarter of 2017. The below chart compares revenues and EPS for Thermo Fisher Scientific since the first quarter of 2017.
Following a DAPT interruption at one month on patients with a next generation DES, the Onyx ONE Clear Study by Medtronic (MDT) investigates risk of cardiac death, heart attack and stent thrombosis.
Since January 2, Boston Scientific’s (BSX) share price has risen 41.4%. The company posted 6% YoY (year-over-year) organic revenue growth in the first half of 2018. The company is thus expected to witness revenue growth rates in the second half similar to those it witnessed in the first half.
September 10, 2018 - Medtronic plc (MDT) today announced the start of the Onyx ONE Clear Study in the U.S. and Japan that will evaluate one-month dual antiplatelet therapy (DAPT) in high bleeding risk patients implanted with the Resolute Onyx(TM) Drug-Eluting Stent (DES) during percutaneous coronary intervention (PCI).1 The Onyx ONE Clear Study is one of the first studies in the U.S. and Japan designed to investigate safety - such as risk of cardiac death, heart attack and stent thrombosis - following DAPT interruption or discontinuation at one month with a next generation DES. "One-month DAPT duration after coronary stenting in high bleeding risk patients offers the potential to substantially enhance the safety of interventional procedures in these high-risk patients," said Gregg W. Stone, M.D., professor of medicine at Columbia University in New York, and program chair of the Onyx ONE Month DAPT Program.
From January 2–28, 2018, Teleflex (TFX) stock rose from $254.73 to $287.65, which was its high point so far in 2018. During the broader market turmoil in February, it dipped to a low of $242.67 on March 1. Then it made a steady recovery to $280 in June but has corrected again to its current level of $248.
Medtronic plc (NYSE:MDT) saw a decent share price growth in the teens level on the NYSE over the last few months. As a large-cap stock with high coverage by analysts,Read More...
Teleflex’s (TFX) interest expenses increased from $19.89 million in the second quarter of 2017 to $26.65 million in the second quarter of 2018. Its income taxes, on the other hand, decreased from $12.1 million in the second quarter of 2017 to $9.58 million in the second quarter of 2018.
In September, of the 17 analysts covering Intuitive Surgical (ISRG), 11 have given its stock “buy” or higher ratings, five have given it “hold” ratings, and one has given it a “sell” rating.
This translated into a net income per share of $2.25 in the second quarter. Its net income per share was $2.01 in the second quarter of 2017. In July, Intuitive Surgical received FDA clearance for the marketing of its da Vinci EndoWrist Stapler, SureForm 60, which is a single-use stapling instrument with particular uses in bariatric procedures.
How Do Abiomed’s Valuations Look in September? Wall Street analysts estimate Abiomed (ABMD) will report 29.9% growth in revenues to ~$771.0 million in 2019 as compared to $593.7 million in 2018. The earnings per share are expected to be $4.66 in 2019.
As discussed earlier, Abiomed (ABMD) reported revenues of $180.0 million in Q1 2019, a 36% increase as compared to revenues of ~$132.5 million in the first quarter of 2018.